Spark's gene therapy granted 'breakthrough' status
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation to Spark Therapeutics’ late-stage gene therapy SPK-RPE65, which targets a group of blinding conditions, known as inherited retinal dystrophies (IRDs), which are caused by autosomal recessive mutations in the RPE65 gene.